Harmony Advances First Human Study of Orexin 2 Agonist
BP1.15205 enters phase 1 testing as Harmony positions the selective OX2R agonist to broaden treatment choices for narcolepsy and other hypersomnolence disorders.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
